# AGENDA

**New York Cardiovascular Symposium**

## FRIDAY, DECEMBER 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 a.m.</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
</tbody>
</table>
| 6:15 a.m. | **Introductions**                                                                  | Tim Attebery, MBA  
C. Michael Valentine, MD, FACC  
J. Chad Teeters, MD, FACC |
| 7:15 a.m. | **Cardiovascular and Coronary Artery Disease — Challenges in 2018**                |                                                |
| 7:30 a.m. | Noninvasive Approach to Subclinical Arterial Disease in 12,000 Subjects            | Dr. Fuster                                     |
| 8:00 a.m. | Invasive Approach to Clinical Arterial Disease in 3,000 Patients                  | Dr. Zadeh                                      |
| 8:25 a.m. | Noninvasive Approach to Inflammation in Coronary Artery Disease                   | Dr. Ridker                                     |
| 8:50 a.m. | Panel Discussion                                                                   | Drs. Fuster, Zadeh and Ridker                  |
| 9:20 a.m. | Coffee Break                                                                      |                                                |
| 9:40 a.m. | **Session II: Acute Coronary Syndromes**                                          | Dr. Bhatt, Presiding                           |
| 10:05 a.m.| Noninvasive Approach to Subclinical Arterial Disease in 12,000 Subjects           | Dr. Bhatt                                      |
| 10:30 a.m.| Invasive Approach to Clinical Arterial Disease in 3,000 Patients                  | Dr. Hochman                                    |
| 10:55 a.m.| Noninvasive Approach to Inflammation in Coronary Artery Disease                   | Dr. Angiolillo                                  |
| 11:20 a.m.| Panel Discussion                                                                   | Drs. Bhatt, Hochman and Angiolillo             |
| Noon    | Lunch                                                                             |                                                |
| 1:00 p.m.| **Session III: Systemic Arterial Disease — Chronic Coronary Disease, Stroke and Pulmonary Embolism** | Dr. O’Gara, Presiding                          |
| 1:20 p.m.| Noninvasive Approach to Subclinical Arterial Disease in 12,000 Subjects           | Dr. Fuster                                     |
| 1:45 p.m.| Invasive Approach to Clinical Arterial Disease in 3,000 Patients                  | Dr. Hopkins                                     |
| 2:00 p.m.| Noninvasive Approach to Inflammation in Coronary Artery Disease                   | Dr. Angiolillo                                  |
| 2:25 p.m.| Panel Discussion                                                                   | Drs. Bhatt, Hochman and Angiolillo             |

**Note:** The agenda includes presentations on the latest advancements in cardiovascular and coronary artery disease, focusing on new frontiers, acute coronary syndromes, and systemic arterial disease. The goal is to keep learning and bring it back to your patients.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:05 p.m.</td>
<td>Pulmonary Emboli: Diagnosis Based on Suspicion Management Based on the Acute Severity and Degree of Chronic PH</td>
<td>Dr. Goldhaber</td>
</tr>
<tr>
<td>2:25 p.m.</td>
<td>Panel Discussion</td>
<td>Drs. Bax, Fuster, Hopkins and Goldhaber</td>
</tr>
<tr>
<td>2:55 p.m.</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td><strong>Session IV: Trends and Challenges of Approaching Prevention — Health Factors</strong></td>
<td>Dr. Bonow, Presiding</td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.</td>
<td><strong>JACC Seminar: Four Challenges to Enhance Eight Health Factors</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Pathophysiological Effects</td>
<td>Dr. Fuster</td>
</tr>
<tr>
<td></td>
<td>2. Mechanistic/Triggering Factors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Role of Preventive Action</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Competencies for Training</td>
<td></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>1. Nutrition and Diet</td>
<td>Dr. Hu</td>
</tr>
<tr>
<td>3:45 p.m.</td>
<td>2. Healthy Weight</td>
<td>Dr. Lavie</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>3. Physical Activity</td>
<td>Dr. Lavie</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>4. Tobacco Free</td>
<td>Dr. Rigotti</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>5. Blood Pressure</td>
<td>Dr. Muntner</td>
</tr>
<tr>
<td>4:45 p.m.</td>
<td>6. Cholesterol</td>
<td>Dr. Catapano</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>7. Blood Sugar</td>
<td>Dr. Ali</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>8. Psychological Health</td>
<td>Dr. Labarthe</td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td>Panel Discussion</td>
<td>Drs. Fuster, Hu, Lavie, Rigotti, Muntner, Catapano, Ali and Labarthe</td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td>Adjournment</td>
<td></td>
</tr>
<tr>
<td><strong>SATURDAY, DECEMBER 8</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:15 a.m.</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td><strong>Cardio-Pulmonary and Electrical Failure 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Session V: Systolic Heart Failure and Basis for Management</strong></td>
<td>Dr. O’Connor, Presiding</td>
<td></td>
</tr>
<tr>
<td>7:00 a.m.</td>
<td>Evolving Imaging (MRI, PET) as Diagnostic &amp; Prognostic Tools For 7 Cardiomyopathies — Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV, Amyloid CM, Sarcoid &amp; Takotsubo</td>
<td>Dr. Bonow</td>
</tr>
<tr>
<td>7:25 a.m.</td>
<td>Evolving Clinical Genetics &amp; Omics in Myocardial Disease Which or What Subgroup of the 7 Entities Should be Gene Tested</td>
<td>Dr. Mann</td>
</tr>
<tr>
<td>7:50 a.m.</td>
<td>Evolving Understanding of Heart Failure and Preserve Ejection Function Different Biological Phenotypes and Evolving Therapeutic Options</td>
<td>Dr. Miller</td>
</tr>
<tr>
<td>8:20 a.m.</td>
<td>Evolving Therapeutic Approaches to 3 Challenging Cardiomyopathies: Myocarditis, Takotsubo, AL/TTR Amyloid and Non-Compaction LV</td>
<td>Dr. Dec</td>
</tr>
<tr>
<td>8:45 a.m.</td>
<td>LVADs — The 3 Upcoming Challenges</td>
<td>Dr. O’Connor</td>
</tr>
<tr>
<td></td>
<td>1. Indications: Not too Late, Not too Early, Since Risks are High</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. New Biocompatible Devices: Transplant Survival of 10 Years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Device Explanation: How to Approach such a Dream</td>
<td></td>
</tr>
<tr>
<td>9:10 a.m.</td>
<td>Panel Discussion</td>
<td>Drs. Bonow, Mann, Miller, Dec and O’Connor</td>
</tr>
<tr>
<td>Time</td>
<td>Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus</td>
<td>Presenter(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>9:40 a.m.</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Atrial Fibrillation 2018 — The 14 Non Ablation Clinical Challenges</td>
<td>Dr. Fuster</td>
</tr>
<tr>
<td>10:25 a.m.</td>
<td>Atrial Fibrillation: Catheter Ablation — 4 Questions</td>
<td>Dr. Wilber</td>
</tr>
<tr>
<td></td>
<td>Who?, When?, How?, Results of CAVANA.</td>
<td></td>
</tr>
<tr>
<td>10:50 a.m.</td>
<td>Left Atrial Appendage Closure — 4 Questions</td>
<td>Dr. Reddy</td>
</tr>
<tr>
<td>11:15 a.m.</td>
<td>Ventricular Tachycardia: Catheter Ablation — 4 Questions</td>
<td>Dr. Marchlinski</td>
</tr>
<tr>
<td>11:40 a.m.</td>
<td>Follow up of the 3 recent Device Therapeutic Approaches</td>
<td>Dr. Gold</td>
</tr>
<tr>
<td></td>
<td>CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers</td>
<td></td>
</tr>
<tr>
<td>Noon</td>
<td>Panel Discussion</td>
<td>Drs. Fuster, Wilber, Reddy, Marchlinski and Gold</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

**Session VII: Valvular Heart Disease and Aorta — Challenges in 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session VII: Valvular Heart Disease and Aorta — Challenges in 2018</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td>Aortic Valvular Stenosis: 4 Challenging Variables for Management</td>
<td>Dr. Bonow</td>
</tr>
<tr>
<td></td>
<td>Asymptomatic, Known Cardiomyopathy (i.e. Amyloid), Massive LVH</td>
<td>Discussant, Dr. Sharma</td>
</tr>
<tr>
<td></td>
<td>Low Flow/Low Gradient</td>
<td></td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td>Severe Aortic Valvular Stenosis — TVAR in 4 Ages and 4 Etiologies</td>
<td>Dr. O’Gara</td>
</tr>
<tr>
<td></td>
<td>Age 25y Congenital, 50y Bicuspid, 75y Rheumatic, 100y Degenerative</td>
<td>Discussant, Dr. Adams</td>
</tr>
<tr>
<td>2:10 p.m.</td>
<td>Asymptomatic Severe Aortic Regurgitation &amp; Normal EF</td>
<td>Dr. O’Gara</td>
</tr>
<tr>
<td></td>
<td>The Dilated LV as a Key for Surgical Intervention</td>
<td>Discussant, Dr. Bonow</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>The Dilated Thoracic &amp; Abdominal Aorta and Complicating Dissection</td>
<td>Dr. Foster</td>
</tr>
<tr>
<td></td>
<td>Evolving Understanding of the Basic Biology &amp; Management</td>
<td>Discussant, Dr. Adams</td>
</tr>
<tr>
<td>3:00 p.m.</td>
<td>Panel Discussion</td>
<td>Drs. Bonow, Sharma, O’Gara, Adams, Fuster, and Nishimura</td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

**Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40 p.m.</td>
<td>Significant Mitral Regurgitation (Low EF, LVEdD, PH or AF)</td>
<td>Dr. Adams</td>
</tr>
<tr>
<td></td>
<td>2 Etiologies (1ary, 2ary), 3 Approaches (Medical, T. Clipping, Surgical)</td>
<td>Discussant, Dr. Sharma</td>
</tr>
<tr>
<td>4:05 p.m.</td>
<td>Significant Tricuspid Regurgitation (2ary, 1ary), 3 Approaches (Medical, T. Coaptation or Suturing, Surgical)</td>
<td>Dr. Nishimura</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>Hypertrophic Cardiomyopathy — 4 Challenging Questions</td>
<td>Dr. Nishimura</td>
</tr>
<tr>
<td></td>
<td>Genetics/Acquired, Myectomy/3Types, Natural Hx/ICD, Apical Aneurysm</td>
<td></td>
</tr>
<tr>
<td>4:55 p.m.</td>
<td>Panel Discussion</td>
<td>Drs. Adams, Sharma and Nishimura</td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td>Adjournment</td>
<td></td>
</tr>
</tbody>
</table>
### SUNDAY, DECEMBER 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 a.m.</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>7:30 a.m.</td>
<td>Part 1: Progress in Precision Medicine: Merger of Genome Editing and Induced Pluripotent Stem Cells to Decipher CVD</td>
<td>Dr. Wu</td>
</tr>
<tr>
<td>7:55 a.m.</td>
<td>Part 2: Progress in Molecular Cardiovascular Medicine — MicroRNAs and Metabolomics A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies</td>
<td>Dr. Mayr</td>
</tr>
<tr>
<td>8:20 a.m.</td>
<td>Part 3: Progress in Myocardial Regeneration — Exosomes and iPSCs A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies</td>
<td>Dr. Bolli</td>
</tr>
</tbody>
</table>

**Section X: Novelties on Diagnostic and Therapeutic Strategies**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 a.m.</td>
<td>Part 1: Tailor-made Decision Making for Surgical or Percutaneous Revascularization Based on Non-invasive Imaging and Comorbidities</td>
<td>Dr. Serruys</td>
</tr>
<tr>
<td>9:10 a.m.</td>
<td>Part 2: NIH — Hybrid Revascularization in Multi-Vessel Coronary Disease LIMA — to LAD + PCI of non-LAD vs PCI of all Diseased Vessels</td>
<td>Dr. Puskas</td>
</tr>
<tr>
<td>9:35 a.m.</td>
<td>Part 3: Cardiac and Renal Effects of SGLT-2 Inhibitors in Diabetes A New Strategic Possibility for the Treatment of Heart Failure</td>
<td>Dr. Braunwald</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

**Section XI: Aiming at the Future of Medicine**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20 a.m.</td>
<td>Part 1: The Future of Health Education Starting at Pre-School Results in 4,000 Children, at Short, Middle and Long Term</td>
<td>Dr. Fuster</td>
</tr>
<tr>
<td>10:45 a.m.</td>
<td>Part 2: The Future of Children Operated for Congenital Heart Disease Evolving of Heart Teams Integrated by Pediatric &amp; Adult Cardiologists</td>
<td>Dr. Warnes</td>
</tr>
<tr>
<td>11:15 a.m.</td>
<td>PAUL DUDLEY WHITE LECTURE 2018</td>
<td>Dr. Carpentier</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>Course Adjournment</td>
<td></td>
</tr>
</tbody>
</table>

*The course was excellent. There was a good mixture of basic and clinical science.*  
— 2017 Attendee